Cambria Investment Management L.P. Boosts Stock Position in Pfizer Inc. $PFE

Cambria Investment Management L.P. increased its holdings in Pfizer Inc. (NYSE:PFE) by 8.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 397,747 shares of the biopharmaceutical company’s stock after purchasing an additional 30,156 shares during the quarter. Cambria Investment Management L.P.’s holdings in Pfizer were worth $10,135,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Lantern Wealth Advisors LLC lifted its stake in Pfizer by 5.4% in the third quarter. Lantern Wealth Advisors LLC now owns 18,126 shares of the biopharmaceutical company’s stock worth $462,000 after acquiring an additional 925 shares during the period. Vermillion & White Wealth Management Group LLC increased its position in Pfizer by 10.4% during the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 8,547 shares of the biopharmaceutical company’s stock valued at $218,000 after purchasing an additional 806 shares during the period. KERR FINANCIAL PLANNING Corp bought a new position in Pfizer in the 3rd quarter worth $41,000. Manhattan West Asset Management LLC raised its holdings in Pfizer by 4.5% in the 3rd quarter. Manhattan West Asset Management LLC now owns 86,490 shares of the biopharmaceutical company’s stock worth $2,204,000 after purchasing an additional 3,758 shares in the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new stake in shares of Pfizer in the 3rd quarter worth about $20,066,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.5%

NYSE:PFE opened at $27.33 on Thursday. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The firm’s 50-day moving average price is $26.61 and its 200-day moving average price is $25.57. The company has a market capitalization of $155.38 billion, a PE ratio of 20.09 and a beta of 0.47. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same period last year, the company posted $0.63 EPS. Pfizer’s revenue was down 1.2% on a year-over-year basis. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Morgan Stanley set a $27.00 price target on shares of Pfizer and gave the company a “positive” rating in a research report on Tuesday. HSBC raised their price objective on shares of Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday. Citigroup began coverage on Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price on the stock. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research report on Monday, March 2nd. Finally, Wolfe Research set a $24.00 target price on Pfizer and gave the company an “underperform” rating in a research note on Wednesday, December 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $28.14.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase‑2 win for atirmociclib: Pfizer reported positive topline results from the randomized FOURLIGHT‑1 study showing its next‑generation CDK4 inhibitor plus fulvestrant met the primary endpoint and reduced risk of progression or death (~40%). The result strengthens Pfizer’s oncology pipeline and positions atirmociclib as a potential successor/competitive option to existing CDK4/6 therapies. Pfizer Announces Positive Topline Phase 2 Results for Atirmociclib
• Positive Sentiment: Analyst upgrade/price‑target raise: HSBC raised its price target on PFE to $32 and maintained a Buy rating, giving investors an incremental valuation tailwind and signaling analyst confidence in Pfizer’s medium‑term outlook. HSBC Raises Price Target on Pfizer
• Neutral Sentiment: Early liver program progress: Pfizer advanced a Phase‑1 study of PF‑07328948 (liver indication), an early readout that modestly adds breadth to the pipeline but is unlikely to drive material near‑term revenue given its very early stage. Pfizer Advances Early PF-07328948 Liver Study
• Neutral Sentiment: Market/commentary noise: Media/analyst chatter (including TV commentary and bullish opinion pieces) is drawing attention to Pfizer’s broad pipeline and long‑term potential, but these are sentiment drivers rather than new clinical or commercial facts. Expect short‑term volatility around headlines. Jim Cramer Notes Pfizer Has “Got a Lot of Stuff in the Pipeline”
• Negative Sentiment: Study termination in melanoma: Pfizer ended a Phase‑1 study of PF‑08046031 in early‑stage melanoma, trimming one oncology program. While not expected to be material to top‑line forecasts, it marginally reduces pipeline optionality and is a near‑term negative datapoint for investors focused on oncology depth. Pfizer Ends Early-Stage Melanoma Study

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.